Literature DB >> 11745478

Overexpression of MUC1 reconfigures the binding properties of tumor cells.

K M McDermott1, P R Crocker, A Harris, M D Burdick, Y Hinoda, T Hayashi, K Imai, M A Hollingsworth.   

Abstract

Although it is known that adhesion and antiadhesion are essential to the metastatic spread of tumor cells, little is known about the molecules that regulate these processes. MUC1 is overexpressed and aberrantly glycosylated by a variety of tumor cells. Studies described here examined whether tumor-associated MUC1 conferred new binding properties on tumor cell lines. Flow cytometry analysis with soluble P-, E- and L-selectin/IgM chimeric proteins was performed on human pancreatic (S2-013 and Panc-1) and colon (Caco-2) tumor cells. S2-013 cells bound E- and P-selectin and Caco-2 cells bound P-selectin. Epitope-tagged MUC1 (MUC1F) expressed by S2-013, Panc-1 and Caco-2 tumor cells did not bind to P-, E- or L-selectin. Overexpression of MUC1F on the surface of S2-013 cells blocked the interactions of E-selectin to tumor-associated ligand(s) but did not affect accessibility of monoclonal antibodies to other cell surface glycoproteins (CD9, CD44). Cell aggregation assays revealed that MUC1F expressed by S2-013 cells was able to bind to intracellular adhesion molecule-1 expressed on B cells. Overexpression of MUC1F containing a targeted mutation (the tandem repeat domain entirely or partially deleted) did not block the binding of E-selectin to its S2-013-associated ligand. These results demonstrate for the first time that the heavily O-glycosylated tandem repeat domain of MUC1 can simultaneously mediate and block binding to adhesion molecules with some molecular specificity and further support the hypothesis that MUC1 plays a dual role in the metastatic spread of tumor cells. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745478     DOI: 10.1002/ijc.1554

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  38 in total

1.  Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.

Authors:  Isabel Correa; Tim Plunkett; Anda Vlad; Arron Mungul; Jessica Candelora-Kettel; Joy M Burchell; Joyce Taylor-Papadimitriou; Olivera J Finn
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

2.  Holothurian glycosaminoglycan inhibits metastasis via inhibition of P-selectin in B16F10 melanoma cells.

Authors:  Zhiqiang Yue; Aiyun Wang; Zhijie Zhu; Li Tao; Yao Li; Liang Zhou; Wenxing Chen; Yin Lu
Journal:  Mol Cell Biochem       Date:  2015-08-30       Impact factor: 3.396

3.  MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1.

Authors:  Jennifer J Rahn; Jeffrey W Chow; Garnet J Horne; Brian K Mah; Joanne T Emerman; Pat Hoffman; Judith C Hugh
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

4.  Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression.

Authors:  Pankaj K Singh; Michelle E Behrens; John P Eggers; Ronald L Cerny; Jennifer M Bailey; Kandavel Shanmugam; Sandra J Gendler; Eric P Bennett; Michael A Hollingsworth
Journal:  J Biol Chem       Date:  2008-07-14       Impact factor: 5.157

Review 5.  Membrane mucins of the intestine at a glance.

Authors:  Thaher Pelaseyed; Gunnar C Hansson
Journal:  J Cell Sci       Date:  2020-03-13       Impact factor: 5.285

Review 6.  Mucin-based targeted pancreatic cancer therapy.

Authors:  Maria P Torres; Subhankar Chakraborty; Joshua Souchek; Surinder K Batra
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 7.  Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.

Authors:  Donella M Beckwith; Maré Cudic
Journal:  Semin Immunol       Date:  2020-01-09       Impact factor: 11.130

8.  MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas.

Authors:  M Saitou; M Goto; M Horinouchi; S Tamada; K Nagata; T Hamada; M Osako; S Takao; S K Batra; T Aikou; K Imai; S Yonezawa
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

9.  Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis.

Authors:  Qicheng Zhao; Monica Barclay; John Hilkens; Xiuli Guo; Hannah Barrow; Jonathan M Rhodes; Lu-Gang Yu
Journal:  Mol Cancer       Date:  2010-06-18       Impact factor: 27.401

10.  Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface.

Authors:  Qicheng Zhao; Xiuli Guo; Gerard B Nash; Philip C Stone; John Hilkens; Jonathan M Rhodes; Lu-Gang Yu
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.